Gobbi C, et al. Real-world data from the TACO (teriflunomide in relapsing remitting multiple sclerosis patients assessing clinical benefit and patient-reported outcomes) study. Poster 1371. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Solanezumab bij preklinische ziekte van Alzheimer: fase III-resultaten
okt 2023 | Dementie